Jordan Valley Dermatology Center

South Jordan, Utah 84095

2 studies enrolling now · 14 studies all time

What they study most

Alopecia Areata, Androgenetic Alopecia, Atopic Dermatitis, Atoptic Dermatitis, Hidradenitis Suppurativa, Hidradenitis Suppurativa (HS), Non-segmental Vitiligo, NonSegmental Vitiligo

Studies at this site

• Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo — Recruiting now
• A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• Phase 2b Study of EVO756 in Adults With Atopic Dermatitis — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. — Stopped early
• An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis — Stopped early
• A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. — Stopped early
• Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA — Completed
• Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis — Completed
• A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis — Stopped early
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) — Completed
• A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis — Completed